-
10010517-5A selective and potent inhibitor of 2,3-oxidosqualene cyclase (OSC) in vivo with an ED50 value of 0.2-0.
-
10010517-50A selective and potent inhibitor of 2,3-oxidosqualene cyclase (OSC) in vivo with an ED50 value of 0.2-0.
-
11022-10A triple receptor tyrosine kinase inhibitor, blocking signaling through VEGFR (IC50 = 13-34 nM), PDGFR (IC50 = 59-65 nM), and FGFR (IC50 = 37-610 nM) inhibits angiogenesis has potential applications in various forms of cancer and pulmonary
-
11022-100A triple receptor tyrosine kinase inhibitor, blocking signaling through VEGFR (IC50 = 13-34 nM), PDGFR (IC50 = 59-65 nM), and FGFR (IC50 = 37-610 nM) inhibits angiogenesis has potential applications in various forms of cancer and pulmonary
-
11022-50A triple receptor tyrosine kinase inhibitor, blocking signaling through VEGFR (IC50 = 13-34 nM), PDGFR (IC50 = 59-65 nM), and FGFR (IC50 = 37-610 nM) inhibits angiogenesis has potential applications in various forms of cancer and pulmonary
-
16608-1A mixed-type non-competitive inhibitor of telomerase (IC<sub>50</sub> = 93 nM) that has little effect on several mammalian DNA and RNA polymerases, bacterial DNA helicase, or HIV-1 reverse transcriptase induces senescence or apoptosis in cancer
-
16608-10A mixed-type non-competitive inhibitor of telomerase (IC<sub>50</sub> = 93 nM) that has little effect on several mammalian DNA and RNA polymerases, bacterial DNA helicase, or HIV-1 reverse transcriptase induces senescence or apoptosis in cancer
-
16608-5A mixed-type non-competitive inhibitor of telomerase (IC<sub>50</sub> = 93 nM) that has little effect on several mammalian DNA and RNA polymerases, bacterial DNA helicase, or HIV-1 reverse transcriptase induces senescence or apoptosis in cancer
-
16608-50A mixed-type non-competitive inhibitor of telomerase (IC<sub>50</sub> = 93 nM) that has little effect on several mammalian DNA and RNA polymerases, bacterial DNA helicase, or HIV-1 reverse transcriptase induces senescence or apoptosis in cancer
-
11492-1Selective and irreversible dual inhibitor of EGFR and HER2 kinase activity (IC50s = 0.5 and 14 nM, respectively) suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines, and at 20 mg/kg, induces tumor
-
11492-10Selective and irreversible dual inhibitor of EGFR and HER2 kinase activity (IC50s = 0.5 and 14 nM, respectively) suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines, and at 20 mg/kg, induces tumor
-
11492-5Selective and irreversible dual inhibitor of EGFR and HER2 kinase activity (IC50s = 0.5 and 14 nM, respectively) suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines, and at 20 mg/kg, induces tumor